Intriguingly, among 66 significant HRR-associated enhancers in our CRISPRi screen, two are located proximal to NF1 and another two are in the vicinity of NF2. This indicates that loss of NF1 or NF2 expression will benefit tumor growth and thus primarily confer vemurafenib resistance. This evidence concerns the gene NF1 and neoplasm.